MaxCyte IPO Presentation Deck

FDA Master File Helps Customers Efficiently Navigate Path to the Clinic Established in 2002, MaxCyte Master File/Technical Files now referenced in over 30 clinical trials Current countries: • US, Canada, Japan; and UK and Austria Discussions underway with additional regulatory authorities: Australia, Germany, Thailand and China Allows MaxCyte to issue a letter of authorization (LOA) to cell therapy partners for clinical trials in US and countries listed above LOA allows partners to instantly reference all the information in the Master File as part of their own cell therapy product submission to regulatory authorities July 2021 Information in the Master File remains confidential File has been updated with every substantial change to EP systems CONFIDENTIAL M MaxCyte

View entire presentation